Nevro reports Q4 EPS (54c), consensus (49c)

Reports Q4 revenue $113.8M, consensus $113.4M. "We were really encouraged by the progress in our business in the fourth quarter, as evidenced by the steady pick-up in trial activity that continued to improve from last quarter, as well as the ongoing improvement in permanent implant volumes," said CEO D. Keith Grossman. "Our PDN progress with referring clinicians, payers and clinical societies exceeded our expectations in the first full year of approval, and we are looking forward to continuing to develop this exciting growth platform this year. The limited launch of our new HFX iQ system has been very well received, and as a result, we look forward to leading the way with the first big data-backed, AI-powered SCS system that gets smarter over time, learning from patient responses to deliver personalized relief to patients. I’m very pleased with the building blocks that are now in place for attractive growth and leverage going forward, and we believe the challenges to our market will gradually but steadily continue to improve throughout 2023 and beyond."